Indications
Reagila is indicated for the treatment of schizophrenia in adult patients.
Composition
- Active substance
- cariprazine hydrochloride
- International name (INN)
- cariprazine
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Reagila
- Active substance
- cariprazine hydrochloride
- ATC code
- N05AX15
- Group
- Nervous system
- Therapeutic area
- Schizophrenia
- Marketing authorisation holder
- Gedeon Richter
- Status
- Authorised
- EU authorisation
- 13 Jul 2017